Anne-Marie Koop

8 303 N-terminal pro-brain natriuretic peptide as a marker of right ventricular dysfunction in patients with tetralogy of Fallot after surgical repair. Chest The American College of Chest Physicians; 2005;128:2563–2570. 42. Torbicki A, Kurzyna M, Kuca P, Fijałkowska A, Sikora J, Florczyk M, Pruszczyk P, Burakowski J, Wawrzyńska L. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844–848. 43. Schuuring MJ, Riel ACMJ van, Vis JC, Duffels MG, Straalen JP van, Boekholdt SM, Tijssen JGP, Mulder BJM, Bouma BJ. High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. Congenit Heart Dis 2013;8:520–526. 44. Zelniker T, Uhlmann L, Spaich S, Friedrich J, Preusch MR, Meyer FJ, Katus HA, Giannitsis E. Novel biomarkers for risk stratification in pulmonary arterial hypertension. ERJ open Res 2015;1:1–9. 45. Koop AMC, Hagdorn QAJ, Bossers GPL, Leusden T van, Gerding A, Weeghel M van, Vaz FM, Koonen DPY, Silljé HHW, Berger RMF, Bartelds B. Right ventricular pressure overload alters cardiac lipid composition. Int J Cardiol Elsevier B.V.; 2019;287:96–105. 46. Borgdorff MAJ, Koop AMC, Bloks VW, Dickinson MG, Steendijk P, Sillje HHW, Wiechen MPH van, Berger RMF, Bartelds B. Clinical symptoms of right ventricular failure in experimental chronic pressure load are associated with progressive diastolic dysfunction. J Mol Cell Cardiol Elsevier Ltd; 2015;79:244–253. 47. Haehling S Von, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, Rozentryt P, Vassanelli C, Struck J, Banasiak W, Ponikowski P, Kremastinos D, Bergmann A, Morgenthaler NG, Anker SD. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010;12:484–491. 48. Tsuruda T, Kato J, Kitamura K, Kuwasako K, Imamura T, Koiwaya Y, Tsuji T, Kangawa K, Eto T. Adrenomedullin: a possible autocrine or paracrine inhibitor of hypertrophy of cardiomyocytes. Hypertension 1998;31:505–510. 49. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21:138–167. 50. Khan A, Alsahli M, Rahmani A. Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives. Med Sci 2018;6:33. 51. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003;108:1440–1445. 52. Tang WHW, Brennan ML, Philip K, Tong W, Mann S, Lente F Van, Hazen SL. Plasma Myeloperoxidase Levels in Patients With Chronic Heart Failure. Am J Cardiol 2006;98: 796–799. 53. Tang WHW, Tong W, Troughton RW, Martin MG, Shrestha K, Borowski A, Jasper S, Hazen SL, Klein AL. Prognostic Value and Echocardiographic Determinants of Plasma Myeloperoxidase Levels in Chronic Heart Failure. J Am Coll Card iol 2007;49:2364–2370. 54. Peters THF, Sharma HS, Yilmaz E, Bogers AJJC. Quantitative analysis of collagens and fibronectin expression in human right ventricular hypertrophy. Ann N Y Acad Sci 1999;874:278–285.